Who are Pemetrexed + Cisplatin /Carboplatin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pemetrexed + oral folinic acid rescue, Intrathecal injection of pemetrexed, Pemetrexed disodium f Injection, Pemetrexed+carboplatin/Cisplatin, Pemetrexed+Cisplatin or Carboplatin, Pemetrexed therapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pemetrexed-cisplatin-carboplatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Pemetrexed + Cisplatin /Carboplatin — Competitive Intelligence Brief

Pemetrexed + Cisplatin /Carboplatin (Pemetrexed + Cisplatin /Carboplatin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antineoplastic agent. Area: Oncology.

phase 3 Antineoplastic agent Thymidylate synthase, Dihydrofolate reductase, Glycinamide ribonucleotide formyltransferase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Pemetrexed + Cisplatin /Carboplatin (Pemetrexed + Cisplatin /Carboplatin) — Jiangsu Hansoh Pharmaceutical Co., Ltd.. Pemetrexed is a folate antagonist that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, leading to cell death in rapidly dividing cancer cells. Cisplatin and Carboplatin are platinum-based chemotherapeutic agents that induce DNA crosslinks, causing cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Pemetrexed + Cisplatin /Carboplatin TARGET	Pemetrexed + Cisplatin /Carboplatin	Jiangsu Hansoh Pharmaceutical Co., Ltd.	phase 3	Antineoplastic agent	Thymidylate synthase, Dihydrofolate reductase, Glycinamide ribonucleotide formyltransferase
Pemetrexed + oral folinic acid rescue	Pemetrexed + oral folinic acid rescue	Radboud University Medical Center	marketed	Antifolate antimetabolite	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase
Intrathecal injection of pemetrexed	Intrathecal injection of pemetrexed	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	marketed	Antifolate antimetabolite	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase
Pemetrexed disodium f Injection	Pemetrexed disodium f Injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Antifolate antimetabolite	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase
Pemetrexed+carboplatin/Cisplatin	Pemetrexed+carboplatin/Cisplatin	Suzhou Puhe Pharmaceutical Technology Co., LTD	phase 3	Antifolate antimetabolite + platinum-based chemotherapy combination	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase; DNA (platinum agents)
Pemetrexed+Cisplatin or Carboplatin	Pemetrexed+Cisplatin or Carboplatin	Sichuan Baili Pharmaceutical Co., Ltd.	phase 3	Antifolate antimetabolite + platinum-based chemotherapy combination	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase; DNA (platinum agents)
Pemetrexed therapy	Pemetrexed therapy	The First Affiliated Hospital with Nanjing Medical University	phase 3	Antifolate antimetabolite	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antineoplastic agent class)

Acrotech Biopharma Inc. · 1 drug in this class
Asan Medical Center · 1 drug in this class
AstraZeneca · 1 drug in this class
Beijing Biostar Pharmaceuticals Co., Ltd. · 1 drug in this class
Cephalon, Inc. · 1 drug in this class
Jiangsu Hansoh Pharmaceutical Co., Ltd. · 1 drug in this class
Seattle Project Corporation · 1 drug in this class
Taiho Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pemetrexed + Cisplatin /Carboplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/pemetrexed-cisplatin-carboplatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab